US2004102411A1PendingUtilityA1

DNA vaccine against feline immunodeficiency virus

55
Priority: Jun 14, 1999Filed: Sep 26, 2003Published: May 27, 2004
Est. expiryJun 14, 2019(expired)· nominal 20-yr term from priority
Inventors:Ruitang DengEric FuogSuresh JeevarathnamAnthony JohnsonWilliam KoertjeMark RothMichael ShepperdDavid W. WheelerTerecita Yule
A61K 2039/545A61P 31/12A61K 39/12A61K 2039/552C12N 2740/15034A61K 2039/525A61K 39/21A61K 2039/53A61P 31/14A61K 2039/54
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A vaccine composition against feline immunodeficiency virus (FIV), comprising an immunologically effective amount of one or more polynucleotide molecules, wherein each polynucleotide molecule comprises a nucleotide sequence selected from a portion of the genome of an FIV strain, or a nucleotide sequence which is a degenerate variant thereof; and a veterinarily acceptable carrier.  
     
     
         2 . The vaccine composition of  claim 1 , wherein each polynucleotide molecule comprises a nucleotide sequence encoding one or more of a structural or non-structural protein from an FIV strain, or a combination thereof.  
     
     
         3 . The vaccine composition of  claim 2 , wherein the structural protein is selected from the group consisting of the GAG polyprotein, MA, CA, NC, the ENV polyprotein, SU and TM, and the non-structural protein is selected from the group consisting of the POL polyprotein, PR, RT, DU, IN, Rev, Vif and ORF2.  
     
     
         4 . The vaccine composition of  claim 3 , wherein the FIV proteins are selected from the group consisting of GAG, MA, CA, NC, ENV, SU, TM, DU and PR.  
     
     
         5 . The vaccine composition of  claim 2 , wherein the one or more polynucleotide molecules encode a combination of FIV proteins.  
     
     
         6 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules comprise nucleotide sequences encoding at least two different FIV proteins selected from FIV structural and FIV non-structural proteins; 
 provided that when the one or more polynucleotide molecules encode the ENV and NC proteins from FIV, they also encode at least one other FIV structural or non-structural protein.    
     
     
         7 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules comprise nucleotide sequences encoding at least one FIV structural protein and at least one FIV non-structural protein.  
     
     
         8 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise nucleotide sequences encoding at least four different FIV proteins selected from among the FIV structural and FIV non-structural proteins.  
     
     
         9 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise nucleotide sequences encoding at least five different FIV proteins selected from among the FIV structural and FIV non-structural proteins.  
     
     
         10 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise nucleotide sequences encoding at least six different FIV proteins selected from among the FIV structural and FIV non-structural proteins.  
     
     
         11 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise nucleotide sequences encoding at least seven different FIV proteins selected from among the FIV structural and FIV non-structural proteins.  
     
     
         12 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise a nucleotide sequence encoding at least one FIV structural protein and a nucleotide sequence encoding at least one FIV regulatory protein.  
     
     
         13 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise a nucleotide sequence encoding at least one FIV POL protein and a nucleotide sequence encoding at least one FIV regulatory gene.  
     
     
         14 . The vaccine composition of  claim 5 , wherein the one or more polynucleotide molecules of the vaccine composition comprise a nucleotide sequence encoding at least one FIV structural protein, a nucleotide sequence encoding at least one FIV POL protein, and a nucleotide sequence encoding at least one FIV regulatory protein.  
     
     
         15 . The vaccine composition of  claim 5 , comprising one or more polynucleotide molecules comprising nucleotide sequences encoding a combination of FIV proteins, which combination is selected from the group consisting of GAG/MA/CA/NC; GAG/ENV; GAG/MA/CA/NC/ENWSU/TM; MA/CA/NC; GAG/MA/NC/DU/PR; and MA/CA/NC/SU/TM.  
     
     
         16 . The vaccine composition of  claim 5 , wherein the nucleotide sequences encoding the combination of FIV proteins are on the same polynucleotide molecule  
     
     
         17 . The vaccine composition of  claim 2 , further comprising a supplemental component selected from the group consisting of an adjuvant, a cytokine, a polynucleotide molecule comprising a nucleotide sequence encoding a cytokine, and an agent to facilitate cellular uptake of polynucleotide molecules by a cat to which the vaccine composition has been administered.  
     
     
         18 . The vaccine composition of  claim 2 , wherein the polynucleotide molecule is DNA.  
     
     
         19 . The vaccine composition of  claim 18 , wherein the DNA is in the form of a plasmid or a viral vector.  
     
     
         20 . The vaccine composition of  claim 18 , wherein the polynucleotide molecule is microencapsulated, or coated onto gold particles.  
     
     
         21 . A method of preparing a vaccine composition against feline immunodeficiency virus (FIV), comprising combining an immunologically effective amount of one or more polynucleotide molecules, wherein each polynucleotide molecule comprises a nucleotide sequence selected from a portion of the genome of an FIV strain, or a nucleotide sequence which is a degenerate variant thereof, with a veterinarily acceptable carrier.  
     
     
         22 . The method of  claim 21 , wherein the one or more polynucleotide molecules comprise nucleotide sequences encoding one or more of a structural or non-structural protein from an FIV strain, or a combination thereof.  
     
     
         23 . The method of  claim 22 , wherein the structural protein is selected from the group consisting of the GAG polyprotein, MA, CA, NC, the ENV polyprotein, SU and TM, and the non-structural protein is selected from the group consisting of the POL polyprotein, PR, RT, DU, IN, Rev, Vif and ORF2.  
     
     
         24 . The method of  claim 21 , further comprising adding to the vaccine composition a supplemental component selected from the group consisting of an adjuvant, a cytokine, a polynucleotide molecule comprising a nucleotide sequence encoding a cytokine, and an agent to facilitate cellular uptake of polynucleotide molecules by a cat to which the vaccine composition has been administered.  
     
     
         25 . The method of  claim 21 , wherein the polynucleotide molecule is DNA.  
     
     
         26 . The method of  claim 25 , wherein the DNA is in the form of a plasmid or a viral vector.  
     
     
         27 . The method of  claim 21 , further comprising microencapsulating at least one of the polynucleotide molecules, or coating at least one of the polynucleotide molecules onto gold particles.  
     
     
         28 . A method of vaccinating a cat against feline immunodeficiency virus (FIV), comprising administering to the cat the vaccine composition of  claim 1 .  
     
     
         29 . The method of  claim 28 , wherein the vaccine composition is administered parenterally, orally, intranasally, intramuscularly, intradermally, subcutaneously, or by use of gene gun.  
     
     
         30 . A kit for vaccinating a cat against feline immunodeficiency virus (FIV), comprising a first container comprising the vaccine composition of  claim 1 .  
     
     
         31 . The kit of  claim 30 , wherein the vaccine composition is in lyophilized form.  
     
     
         32 . The kit of  claim 31 , further comprising a second container comprising a sterile diluent useful to dilute or rehydrate the vaccine composition in the first container.

Join the waitlist — get patent alerts

Track US2004102411A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.